SEC Form 4 · accession 0001808317-26-000001

Akebia Therapeutics, Inc. · AKBA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jun 17, 2026

Accepted (ET)

Jun 22, 2026 · 4:24 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001517022

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jun 17, 2026	A	35,700	$0.00	A	169,081	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to buy)^F2	$1.02	Jun 17, 2026	A	53,600	A	Jun 17, 2027	Jun 17, 2036	Common Stock	53,600	53,600	D

F1The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
F2The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.